Papers/PMID:35037116
Improvement of adjunctive berberine treatment on negative symptoms in patients with schizophrenia.
European archives of psychiatry and clinical neuroscience2022The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
berberine — decreases C-reactive protein concentration
Evidence strength: very limited.Findingreplicated ×2“From the baseline to the 8th week, the plasma CRP concentration decreased in the berberine group, while increased in the placebo group (F = 5.373; p = 0.024).”
Quoted verbatim from Improvement of adjunctive berberine treatment on negative symptoms in patients with schizophrenia.. - Study
- RCT
- Duration
- 8 weeks
- Dose
- berberine 900 mg/day, oral, 8 weeks
- Population
- patients with schizophrenia, berberine given adjunctive to a single atypical antipsychotic drug
Improvement of adjunctive berberine treatment on negative symptoms in patients with schizophrenia.2022PMID:3503711610.1007/s00406-021-01359-4Permalink